Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Stephens & Co. Maintains Overweight on Apyx Medical, Lowers Price Target to $5

Author: Benzinga Newsdesk | November 10, 2023 11:44am
Stephens & Co. analyst George Sellers maintains Apyx Medical (NASDAQ:APYX) with a Overweight and lowers the price target from $8 to $5.

Posted In: APYX

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist